Biohaven initiates trial studying BHV-2100 for treatment of migraines

Biohaven announced that it has initiated a pivotal Phase 2 study of the potential first-in-class, orally administered TRPM3 antagonist, BHV-2100, in the acute treatment of migraine. The pivotal Phase 2 study is a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of two doses of BHV-2100 in the acute treatment of migraine. The trial is designed to support registration with FDA-accepted coprimary endpoints of pain freedom and freedom from most bothersome symptom at 2 hours.